Search Within

Shari Goldfarb

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (2)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (11)
  2. Breast Medicine Service (11)
  3. Department of Medicine (11)
  4. Epidemiology and Biostatistics (11)
  5. GSK Faculty (11)
  6. Health Outcomes Research Group (11)

More Groups

People
  1. Sarat Chandarlapaty (11)
  2. Diana Lake (9)
  3. Gabriella D'Andrea-Carlino (9)
  4. Clifford Hudis (8)
  5. Shanu Modi (8)
  6. Sujata Patil (8)

More People

Years
  1. 2024 (1)
  2. 2018 (1)
  3. 2016 (1)
  4. 2015 (2)
  5. 2014 (3)
  6. 2013 (1)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Cancer Research (3)
  3. Clinical Breast Cancer (1)
  4. European Journal of Cancer (1)
  5. Journal of Nuclear Medicine (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (2)
  4. Society of Nuclear Medicine (1)

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life in patients with malignant wounds treated at a wound care clinic
    Meeting Abstract

    Chen, A.; Dusza, S. W.; Bromberg, J.; Chandarlapaty, S.; Goldfarb, S. B.; Sanford, R. A.; Markova, A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Co-targeting ER and FGFR in patients with ER+/HER2- FGFR amplified (amp) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Syed, U.; Wong, S.; D'Andrea, G.; Lake, D.; Goldfarb, S.; Gajria, D.; Ligresti, L.; Rogado, A.; Reis-Filho, J.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT
    Journal Article

    Ulaner, G. A.; Hyman, D. M.; Ross, D. S.; Corben, A.; Chandarlapaty, S.; Goldfarb, S.; McArthur, H.; Erinjeri, J. P.; Solomon, S. B.; Kolb, H.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S. B.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; Comen, E. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save